DNA methylation is a widely studied epigenetic modification with crucial roles in gene regulation, development, and disease, particularly in cancer. It has immense potential as a biomarker for early detection, monitoring, and treatment response.
CUTANA™ DNA Methylation assays, built upon our industry-leading CUT&RUN technology, offer the optimal combination of low cost and comprehensive insights.
An Affordable Solution for Genome-Wide DNA Methylation Sequencing
DNA methylation researchers face a tough choice: expensive whole-genome bisulfite sequencing (WGBS), or limited insights from arrays, reduced representation bisulfite sequencing (RRBS), and targeted panels. Bisulfite conversion also damages DNA, resulting in potential biases that can complicate data analysis.
CUTANA™ meCUT&RUN solves this challenge by selectively enriching methylated DNA, delivering high-quality, genome-wide insights at a fraction of the sequencing required for WGBS.
Next-Gen Multiomic Profiling of DNA Methylation and Chromatin Proteins
Understanding gene regulation requires a complete picture of chromatin structure, including both DNA methylation and chromatin protein binding. Traditional approaches like ChIP-seq and bisulfite sequencing are expensive, time-consuming, and require complex data integration. Moreover, these analyses cannot directly reveal how epigenetic features interact at the same loci.
CUTANA™ Multiomic CUT&RUN solves these problems by mapping chromatin proteins and DNA methylation together in a single reaction, capturing novel insights to drive biological discovery.
Related Blog: A Comprehensive Guide to DNA Methylation Sequencing Technologies
Need more Information about CUTANA™ DNA Methylation assays? Our team is happy to help!
PHONE NUMBER: +1-855-374-2461
EMAIL: MARKETING@EPICYPHER.COM
© EPICYPHER 2025